Course Provider
Learning Objectives
Participants will discuss the updated NCCN Guidelines and application of immune checkpoint inhibitors (ICIs) for clinical management of locally advanced/metastatic esophagogastric/esophagogastric junction (EGJ) cancer.
Participants will evaluate available clinical evidence for biomarker-directed treatment with ICIs for frontline treatment of locally advanced/metastatic esophagogastric/EGJ cancer, especially in patients with microsatellite instability high (MSI-H)/mismatch repair deficient (dMMR) tumors.
Participants will integrate nutritional support for patients with locally advanced/ metastatic esophagogastric/EGJ cancer.